Nevro Corp (NYSE:NVRO) Director Kevin C. Oboyle acquired 1,675 shares of the company’s stock in a transaction dated Wednesday, June 5th. The stock was acquired at an average price of $60.00 per share, for a total transaction of $100,500.00. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website.
NYSE NVRO traded up $0.26 during mid-day trading on Monday, hitting $65.09. The stock had a trading volume of 237,200 shares, compared to its average volume of 617,194. Nevro Corp has a 52-week low of $34.75 and a 52-week high of $75.98. The firm has a market cap of $1.98 billion, a P/E ratio of -39.69 and a beta of 0.29. The stock has a 50 day moving average price of $61.74. The company has a current ratio of 6.30, a quick ratio of 4.87 and a debt-to-equity ratio of 0.83.
Nevro (NYSE:NVRO) last released its quarterly earnings results on Thursday, May 9th. The medical equipment provider reported ($1.45) earnings per share for the quarter, missing the consensus estimate of ($0.66) by ($0.79). The company had revenue of $82.10 million for the quarter, compared to analysts’ expectations of $87.47 million. Nevro had a negative return on equity of 31.84% and a negative net margin of 19.79%. The business’s quarterly revenue was down 6.3% on a year-over-year basis. During the same period in the previous year, the business posted ($0.59) EPS. Sell-side analysts expect that Nevro Corp will post -3.83 EPS for the current year.
NVRO has been the subject of a number of recent research reports. ValuEngine raised Nevro from a “hold” rating to a “buy” rating in a research report on Wednesday, May 15th. Zacks Investment Research raised Nevro from a “strong sell” rating to a “hold” rating in a report on Tuesday, May 14th. Wells Fargo & Co reduced their price target on Nevro from $75.00 to $70.00 and set an “outperform” rating for the company in a report on Monday, May 13th. Morgan Stanley reduced their price target on Nevro from $70.00 to $64.00 and set an “overweight” rating for the company in a report on Friday, May 10th. Finally, JMP Securities reduced their price target on Nevro from $80.00 to $70.00 and set a “market outperform” rating for the company in a report on Friday, May 10th. Two analysts have rated the stock with a sell rating, four have issued a hold rating and seven have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $57.83.
Nevro Corp., a medical device company, provides products for the patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain.
Recommended Story: What is a conference call?
Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.